Abbonarsi

The intranasal administration of Carthamus tinctorius L. extract/phospholipid complex in the treatment of cerebral infarction via the TNF-?/MAPK pathway - 27/10/20

Doi : 10.1016/j.biopha.2020.110563 
Yu Wang a, 1, Yajun Shi a, b, , 1 , Junbo Zou a, b, Xiaofei Zhang a, b, Mei Wang a, b, Dongyan Guo a, b, Guiyuan Lv c, Jie Su c, Ting Wang c
a Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, China 
b Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, China 
c College of Pharmaceutical Science, No. 548, Binwen Road, Binjiang District, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310014, China 

Corresponding author at: Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese Medicine, Xixian New Area, Xianyang, 712046, China.Department of PharmaceuticsCollege of PharmacyShaanxi University of Chinese MedicineXixian New AreaXianyang712046China

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 13
Iconografia 11
Video 0
Altro 0

Graphical abstract

In this study, we used database retrieval to select the main chemical compositions and disease targets of traditional Chinese medicine and constructed the composition-target-disease network. GO enrichment analysis and KEGG enrichment pathway analysis were deployed via the R software package. Our aim was to explore potential pathways underlying the action of Safflower in the treatment of CI, to establish a model MCAO, and to study the mechanisms associated with the action of Safflower at the molecular level.




Il testo completo di questo articolo è disponibile in PDF.

Highlights

We identified 52 effective targets for Safflower in the treatment of CI.
We confirmed that the mechanism responsible for the action of Safflower in the treatment of CI was the CASP3 mediation of the TNF-α / MAPK pathway.
Our analyses identified several targets, including TNF-α, CASP3, MAP3K1, JNK, AP1, IL-1 β, and IL-6.
Safflower had a protective effect on CI by improving blood circulation, inhibiting apoptosis and protecting the brain cells.
Our results provide preliminary evidence for the pharmacological mechanism of Safflower in the treatment of CI.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Carthamus tinctorius L.(Safflower), a herbal formula from Traditional Chinese Medicine (TCM), has been widely used for the treatment of cardio-cerebrovascular diseases, particularly cerebral infarction (CI) or cerebral ischemia-reperfusion injury. However, we know very little about the specific mechanisms associated with the therapeutic effect of Safflower on CI. In this study, we used a network pharmacology-based approach, together with rat model of CI, to gain more insight into of such mechanisms. Our analysis showed that Safflower contains 52 active compounds that target 247 genes, which were also cross-referenced with 299 genes associated with CI. Consequently, we identified 52 target genes in Safflower that were associated with CI. These 52 target genes were analyzed by gene ontology (GO) enrichment analysis, leading to the identification of 1491 biological process items, 90 molecular function items and 19 cell assembly items. Eighty-nine pathways were generated by KEGG enrichment (P < 0.05). Next, we investigated the effect of the extract of safflower (ES) and Safflower extract phospholipid complex (ESPC), delivered via the nasal route, on an animal model of the middle cerebral artery occlusion (MCAO). Our data confirmed that Safflower was able to treat CI by the regulating the TNF-α/MAPK pathway via CASP3. The therapeutic effect of ES and ESPC on CI acts by improving the circulation of blood in the central nervous system, reducing the inflammatory reaction, inhibiting apoptosis, and by protecting brain nerve cells from injury.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : Safflower, CI, GO, MCAO, ES, ESPC

Keywords : Carthamus tinctorius L., Cerebral infarction, TNF-α/MAPK pathway, Safflower extract phospholipid complex, Network pharmacology


Mappa


© 2020  The Author(s). Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 130

Articolo 110563- Ottobre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Ursolic acid protects chondrocytes, exhibits anti-inflammatory properties via regulation of the NF-?B/NLRP3 inflammasome pathway and ameliorates osteoarthritis
  • Chunli Wang, Yan Gao, Zike Zhang, Cheng Chen, Qingjia Chi, Kang Xu, Li Yang
| Articolo seguente Articolo seguente
  • Lychee seed polyphenol inhibits A?-induced activation of NLRP3 inflammasome via the LRP1/AMPK mediated autophagy induction
  • Wen-Qiao Qiu, Rong Pan, Yong Tang, Xiao-Gang Zhou, Jian-Ming Wu, Lu Yu, Betty Yuen-Kwan Law, Wei Ai, Chong-Lin Yu, Da-Lian Qin, An-Guo Wu

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.